Show simple item record

dc.contributor.authorRotea-Salvo, Sandra
dc.contributor.authorMartínez-Pradeda, Alejandro
dc.contributor.authorFernández-Oliveira, Carla
dc.contributor.authorGiménez-Arufe, Víctor
dc.contributor.authorBalboa-Barreiro, Vanesa
dc.contributor.authorMargusino-Framiñán, Luis
dc.contributor.authorMena-De-Cea, Álvaro
dc.contributor.authorVázquez-Rodríguez, Pilar
dc.contributor.authorCastro-Iglesias, Ángeles
dc.contributor.authorLópez-Calvo, Soledad
dc.contributor.authorMartín-Herranz, Isabel
dc.contributor.authorMíguez-Rey, Enrique
dc.contributor.authorCid-Silva, Purificación
dc.date.accessioned2022-11-21T11:40:41Z
dc.date.available2022-11-21T11:40:41Z
dc.date.issued2021-10-14
dc.identifier.citationRotea-Salvo S, Martínez-Pradeda A, Fernández-Oliveira C, Giménez-Arufe V, Balboa-Barreiro V, Margusino-Framiñán L, Mena-De-Cea Á, Vázquez-Rodríguez P, Castro-Iglesias Á, López-Calvo S, Martín-Herranz I, Míguez-Rey E, Cid-Silva P. Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort. Eur J Hosp Pharm. 2021 Oct 14:ejhpharm-2021-002896. Epub ahead of print.es_ES
dc.identifier.issn2047-9956
dc.identifier.urihttp://hdl.handle.net/2183/32087
dc.description.abstract[Abstract] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) are currently available for HIV patients. Objectives: This study evaluated modifications in the renal safety profile in a large real-world cohort of patients who had received EVG/c/FTC/TAF or DTG/ABC/3TC. Methods: A retrospective observational study of HIV-infected patients who received EVG/c/FTC/TAF or DTG/ABC/3TC between March 2015 and June 2019 at a reference hospital in north-western Spain was conducted. Epidemiological, clinical, immunovirological data and information regarding antiretroviral therapy were recorded. The statistical differences between treatments were calculated. Results: A total of 457 patients were evaluated, 266 using EVG/c/FTC/TAF and 191 using DTG/ABC/3TC. Up to week 120, serum creatinine improved in both study groups among experienced patients (EVG/c/FTC/TAF 1.01±0.24 vs 0.91±0.19, p<0.001; DTG/ABC/3TC 1.08±0.24 vs 1.02±0.31, p<0.001), while in naïve patients serum creatinine remained stable compared with baseline. Statistically significant differences were found in serum creatinine when comparing both treatments at week 48 in experienced (0.94±0.21 vs 1.09±0.28, p<0.001) and naïve patients (0.89±0.16 vs 1.06±0.20, p=0.001), and among experienced patients at week 120 (0.91±0.19 vs 1.02±0.31, p=0.015) for the EVG/c/FTC/TAF and DTG/ABC/3TC groups, respectively. During the follow-up, 39 patients in EVG/c/FTC/TAF and 33 in DTG/ABC/3TC (p=0.449) discontinued treatment. The main reason for stopping treatment was adverse events, which were similar in both groups. Conclusions: During the follow-up, patients experienced changes that were not clinically relevant in both treatment groups. Differences in renal events were not found.es_ES
dc.language.isoenges_ES
dc.publisherBMJes_ES
dc.relation.urihttp://dx.doi.org/10.1136/ejhpharm-2021-002896es_ES
dc.rightsThis article has been accepted for publication in European Journal of Hospital Pharmacy following peer review, and the Version of Record can be accessed online at BMJ web page.es_ES
dc.subjectHIVes_ES
dc.subjectClinical medicinees_ES
dc.subjectDrug-related side effects and adverse reactionses_ES
dc.subjectHospitales_ES
dc.subjectLaboratorieses_ES
dc.subjectSafetyes_ES
dc.titleRenal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohortes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleEuropean Journal of Hospital Pharmacyes_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record